Search

Displaying results 1401 - 1410 of 7687 in total
  1. Drug

    Eculizumab

    go.drugbank.com/drugs/DB01257
    ApprovedInvestigational

    [L6919,A2245,A2246] Eculizumab was granted FDA approval on 16 March 2007.

  2. Drug

    Teglarinad chloride

    go.drugbank.com/drugs/DB05217
    Investigational

    Although the exact mechanism of action has yet to be fully elucidated, GMX1778 appears to antagonize nuclear factor-kappa B (NF-kB) transcription, resulting in the induction of tumor cell apoptosis.

  3. Drug

    Pancrelipase lipase

    go.drugbank.com/drugs/DB13147
    ApprovedInvestigational

    [A32748] The pancrelipase mixture, including pancrelipase lipase, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.[L2510] … [L2509] The pancrelipase lipase is an enzyme secreted by the pancreas that is responsible for the hydrolysis of dietary fat molecules in the human digestive system.

    Mixtures: KREON MIKRO 5000 IU MINIMIKROSFER,
  4. Drug

    Zilganersen

    go.drugbank.com/drugs/DB18161
    ApprovedInvestigational

    [L64096] The FDA approved zilganersen on September 3, 2026 for the treatment of Alexander disease in pediatric and adult patients, making it the first and only disease-modifying treatment for the condition … [L64096] It is administered by intrathecal injection, and requires dilution with an accompanying artificial cerebrospinal fluid diluent before administration.

  5. Drug

    Thiethylperazine

    go.drugbank.com/drugs/DB00372
    ApprovedInvestigationalWithdrawn

    A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent ver...

    Categories: Dopamine D2 Receptor Antagonists
  6. Drug

    Phentolamine

    go.drugbank.com/drugs/DB00692
    ApprovedInvestigational

    While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral

  7. Drug

    Tafenoquine

    go.drugbank.com/drugs/DB06608
    ApprovedInvestigational

    [A35677] It was FDA approved on July 20, 2018.[L3770] … Tafenoquine is an 8-aminoquinoline analogue of primaquine which varies only on the presence of a 5-phenoxy group.

  8. Drug

    Vosoritide

    go.drugbank.com/drugs/DB11928
    ApprovedInvestigational

    Achondroplasia is an autosomal dominant genetic disease and the most common cause of dwarfism in humans. … [A242273] While the remarkably short half-life of endogenous CNP - 2 to 3 minutes due to its rapid degradation by endopeptidases - makes it ineffective as a therapeutic intervention,[A242273] the development

  9. Drug

    Lercanidipine

    go.drugbank.com/drugs/DB00528
    ApprovedInvestigationalWithdrawn

    Lercanidipine is a calcium channel blocker of the dihydropyridine class. It is sold under various commercial names including Zanidip.

    Mixtures: ZANIPRESS 10MG/10MG FTA, ZANIPRESS 20MG/10MG FTA
  10. Drug

    Protein C

    go.drugbank.com/drugs/DB11312
    ApprovedInvestigational

    Protein C is an endogenously occurring plasma protein that plays a key role within the coagulation cascade.

    Mixtures: OCTAPLEX POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500 IU, COFACT 250 IU/10 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADETProducts: CEPROTIN 500 IU IV ENJEKSİYONLUK ÇÖZELTİ İÇİN LİYOFİLİZE TOZ İÇEREN FLAKON